TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15042130

Group type: EXPERIMENTAL
Intervention: AX diet (arabinoxylan-rich bread and muffins)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control diet (control bread and muffins)
Number of subjects: 15
Study: 12968582

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 0
Study: 10485505

Group type: EXPERIMENTAL
Intervention: Extended-release etodolac 1200 mg
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Conventional etodolac 400 mg
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Conventional etodolac 200 mg
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 7591683

Group type: EXPERIMENTAL
Intervention: VMCP with IFN-alpha (2 x 10(6) U, 5 days per week for 12 months)
Number of subjects: 84

Group type: COMPARATOR
Intervention: VMCP alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: VMCP with IFN-alpha (for stage 3 evaluable patients)
Number of subjects: 84

Group type: COMPARATOR
Intervention: VMCP alone (for stage 3 evaluable patients)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: VMCP/IFN induction arm
Number of subjects: 84
Study: 1773929

Group type: EXPERIMENTAL
Intervention: Hexetidine vaginal suppositories (10 mg) applied for five days
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Hexetidine (20 mg/day) applied for five days
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Hexetidine (10 mg/day) applied for three days pre-operatively
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Hexetidine preparation
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Hexetidine prophylaxis
Number of subjects: 224
Study: 7025500

Group type: EXPERIMENTAL
Intervention: O‐(β‐hydroxyethyl)‐rutosides (HR)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 30777950

Group type: EXPERIMENTAL
Intervention: heads‐up 3D vision group
Number of subjects: 20

Group type: COMPARATOR
Intervention: conventional surgery group
Number of subjects: 20
Study: 29040125

Group type: EXPERIMENTAL
Intervention: Minimal incision technique
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard incision technique
Number of subjects: 152
Study: 27026043

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day) + Interferon beta-1a (30 micro g/week)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (Interferon beta-1a 30 micro g/week)
Number of subjects: 95
Study: 25090915

Group type: EXPERIMENTAL
Intervention: General inhibition training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cue‐Specific inhibition training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol No‐Go training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 0
Study: 23078200

Group type: EXPERIMENTAL
Intervention: Maitland mobilisations plus range‐of‐motion exercises
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mulligan SNAGs plus self‐SNAG exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 19820906

Group type: EXPERIMENTAL
Intervention: Radiotherapy in combination with simultaneous chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiation and perioperative chemotherapy
Number of subjects: 0
Study: 17255855

Group type: EXPERIMENTAL
Intervention: PEEP set at 26 cm H2O and lung recruitment performed (40/40-maneuver) followed by tidal volume set at 4 mL/kg (T26R) and PEEP lowered by 2 cm H2O every 4 mins.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PEEP set at 26 cm H2O and lung recruitment performed (40/40-maneuver) followed by tidal volume set at 6 mL/kg (T(end)).
Number of subjects: 18
Study: 15201815

Group type: EXPERIMENTAL
Intervention: Hands-on training with bench model simulators (silicone tubing or live rat vas deferens)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Didactic training alone
Number of subjects: 50
Study: 11914251

Group type: EXPERIMENTAL
Intervention: CEE plus MPA 2.5 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CEE plus MPA 5.0 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: CEE (0.625 mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: CEE alone
Number of subjects: 3
Study: 9210501

Group type: EXPERIMENTAL
Intervention: CsA‐ME (cyclosporine for microemulsion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CsA (original formulation)
Number of subjects: 0
Study: 8217065

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 3621278

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (two with class IC and two with class IA action)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 31958932

Group type: EXPERIMENTAL
Intervention: Tattoo group (endoscopic tattooing with carbon nanoparticles)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tattoo-inoperable patients (chemoradiotherapy after tattooing)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-tattoo-inoperable patients (chemoradiotherapy without tattooing)
Number of subjects: 120
Study: 31055046

Group type: EXPERIMENTAL
Intervention: CALAS 20 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CALAS 40 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CALAS 80 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CALAS 120 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CALAS (all doses)
Number of subjects: 40
Study: 27140680

Group type: EXPERIMENTAL
Intervention: Unilateral resistance training (UNI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bilateral resistance training (BIL)
Number of subjects: 22
Study: 26396164

Group type: EXPERIMENTAL
Intervention: Balance-training programme (three times/week over 12 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Training + physical activity
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 24368613

Group type: EXPERIMENTAL
Intervention: Model-based iterative reconstruction (MBIR)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Adaptive statistical iterative reconstruction (ASIR)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low-dose MBIR
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard-dose FBP
Number of subjects: 65
Study: 23070400

Group type: EXPERIMENTAL
Intervention: Nabilone 0.5 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 30
Study: 19244369

Group type: EXPERIMENTAL
Intervention: Glycomacropeptide (GMP) diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: AA diet
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GMP diet
Number of subjects: 11
Study: 17634486

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 4440
Study: 15354390

Group type: EXPERIMENTAL
Intervention: 10-Hz repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: levodopa/rTMS
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo/rTMS
Number of subjects: 12

Group type: COMPARATOR
Intervention: levodopa/sham stimulation
Number of subjects: 12
Study: 11436671

Group type: EXPERIMENTAL
Intervention: Air‐Viva‐2 circuit
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mapleson‐B circuit
Number of subjects: 16

Group type: COMPARATOR
Intervention: Manual hyperinflation technique
Number of subjects: 16
Study: 10095804

Group type: EXPERIMENTAL
Intervention: Folate administration (0.25 mg day‐1) plus 60 mg day‐1 of Fe2+
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (60 mg day‐1 of Fe2+)
Number of subjects: 30
Study: 7831065

Group type: EXPERIMENTAL
Intervention: TTFCA 60 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TTFCA 120 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 20
Study: 3354874

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg IV
Number of subjects: 8

Group type: COMPARATOR
Intervention: Physostigmine 2.0 mg IV
Number of subjects: 8
Study: 1298332

Group type: EXPERIMENTAL
Intervention: Inhaled Bradykinin (8 mg/mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 10
Study: 568923

Group type: EXPERIMENTAL
Intervention: Explicit sexual stimuli
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nonexplicit sexual stimuli
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 31666084

Group type: EXPERIMENTAL
Intervention: umeclidinium/vilanterol 62.5/25 μg once-daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: umeclidinium 62.5 μg once-daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: salmeterol 50 μg twice-daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: umeclidinium/vilanterol
Number of subjects: 0
Study: 27893938

Group type: EXPERIMENTAL
Intervention: LIVESTRONG at the YMCA exercise program
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study: 25896890

Group type: EXPERIMENTAL
Intervention: Serum bicarbonate >26 mmol/L
Number of subjects: 3586

Group type: EXPERIMENTAL
Intervention: Serum bicarbonate <22 mmol/L
Number of subjects: 3586

Group type: COMPARATOR
Intervention: Serum bicarbonate 22 to 26 mmol/L
Number of subjects: 3586
Study: 23603648

Group type: EXPERIMENTAL
Intervention: Flat lateral decubitus position
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 45-degree tilt lateral decubitus position
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 50
Study: 21314449

Group type: EXPERIMENTAL
Intervention: 30 minutes a day of walking 5 days a week in one continuous long bout (LB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: three short 10-minute bouts (SB) of walking a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 19843669

Group type: EXPERIMENTAL
Intervention: 1C diet (single dose of cruciferous vegetables)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 2C diet (double dose of cruciferous vegetables)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 1C+A diet (single dose of cruciferous and apiaceous vegetables)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: CYP1A2 activity recovery after removal of apiaceous vegetables
Number of subjects: 73
Study: 16915511

Group type: EXPERIMENTAL
Intervention: Monofile, heavy-weight, rigid mesh (group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Smooth, heavy-weight variant of polypropylene (group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Polyglactin/polypropylene compound mesh (group C)
Number of subjects: 90
Study: 14755652

Group type: EXPERIMENTAL
Intervention: Biexponential signal decay observed in the cortex of the intact mouse brain; ADC drop in both components during global ischemia; shift from rapidly diffusing component to slowly diffusing component during global ischemia.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biexponential function applied to erythrocyte samples.
Number of subjects: 0
Study: 11734734

Group type: EXPERIMENTAL
Intervention: Intranasal trivalent influenza vaccine (CAIV) - 3 lots (A/Shenzhen/227/95 (H1N1), A/Wuhan/359/95 (H3N2), B/Harbin/7/94-like)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Placebo (Group 5)
Number of subjects: 474
Study: 9203102

Group type: EXPERIMENTAL
Intervention: PLA barrier (n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ePTFE barrier (n = 14)
Number of subjects: 30
Study: 8477303

Group type: EXPERIMENTAL
Intervention: Milkshake preload
Number of subjects: 0

Group type: COMPARATOR
Intervention: No preload
Number of subjects: 0
Study: 3320595

Group type: EXPERIMENTAL
Intervention: Feedback of GHQ information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no feedback of GHQ information)
Number of subjects: 0
Study: 31537563

Group type: EXPERIMENTAL
Intervention: Preventive health check from the general practitioner (GP)
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1104
Study: 28441097

Group type: EXPERIMENTAL
Intervention: Negative health consequences‐graphic ad
Number of subjects: 7812

Group type: EXPERIMENTAL
Intervention: Negative social consequences‐intended emotive ad
Number of subjects: 7812

Group type: EXPERIMENTAL
Intervention: Benefits of quitting‐informational ad
Number of subjects: 7812

Group type: EXPERIMENTAL
Intervention: Benefits of quitting‐graphic ad
Number of subjects: 7812

Group type: EXPERIMENTAL
Intervention: Antismoking ads viewed alone
Number of subjects: 7812

Group type: EXPERIMENTAL
Intervention: Graphic ads viewed in competitive contexts
Number of subjects: 7812
Study: 25394242

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 405

Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Patients on admission
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Patients by day 7
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Patients with elevated soluble RAGE on admission
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression analysis
Number of subjects: 405
Study: 23276397

Group type: EXPERIMENTAL
Intervention: Prisms‐Active
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Prisms‐Imagery
Number of subjects: 54
Study: 21529247

Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMAC) with bovine bone mineral (BBM)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Bovine bone mineral (BBM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group: 70% BBM and 30% autogenous bone (AB)
Number of subjects: 26
Study: 18485164

Group type: EXPERIMENTAL
Intervention: Immediate repair
Number of subjects: 165

Group type: COMPARATOR
Intervention: Delayed repair (8‐ to 12‐hour delay)
Number of subjects: 165
Study: 16551139

Group type: EXPERIMENTAL
Intervention: Self-administered behavioral family intervention
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Self-administered behavioral family intervention plus brief therapist telephone assistance
Number of subjects: 126
Study: 12105157

Group type: EXPERIMENTAL
Intervention: Aspirin, heparin, and meloxicam
Number of subjects: 120
Study: 10202220

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (50/250 microg bid) via a single Diskus inhaler (combination)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Salmeterol 50 microg bid via one Diskus inhaler and fluticasone propionate 250 microg bid via another (concurrent)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 371
Study: 7753538

Group type: EXPERIMENTAL
Intervention: Venting drilling with intramedullary plug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard cemented hip replacement without venting
Number of subjects: 0
Study: 2407660

Group type: EXPERIMENTAL
Intervention: He‐Ne laser
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7008938

Group type: EXPERIMENTAL
Intervention: Loading course of ICRF-159
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Weekly regimen of ICRF-159
Number of subjects: 82
Study: 31400240

Group type: EXPERIMENTAL
Intervention: Therapist-delivered brief intervention (TBI)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Computer-guided brief intervention (CBI)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 780
Study: 31914437

Group type: EXPERIMENTAL
Intervention: Aflibercept 2 mg intravitreal injections every 4 weeks, adjusted based on CSMT changes
Number of subjects: 48
Study: 30422777

Group type: EXPERIMENTAL
Intervention: Web-based Responsible Beverage Service training (WayToServe - WTS)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Usual and Customary live Responsible Beverage Service training (UC)
Number of subjects: 309
Study: 27471208

Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 1247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study: 23942152

Group type: EXPERIMENTAL
Intervention: Reciprocal/BLS instructor (RBI) group
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Reciprocal/non‐BLS instructor (RNI) group
Number of subjects: 175

Group type: COMPARATOR
Intervention: Traditional/BLS instructor (TBI) group
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Experimental groups (RBI and RNI)
Number of subjects: 175
Study: 23294776

Group type: EXPERIMENTAL
Intervention: Dulaglutide (dula, LY2189265) - a once-weekly glucagon-like peptide-1 analog
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive scheme (stage 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed scheme (stage 2)
Number of subjects: 0
Study: 20175947

Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise program (5-10 minute warm-up, 15 minute walking, 5-10 minute cool-down, three times per week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No exercise program (control group)
Number of subjects: 60
Study: 17278015

Group type: EXPERIMENTAL
Intervention: Iguratimod
Number of subjects: 376

Group type: COMPARATOR
Intervention: Salazosulfapyridine
Number of subjects: 376
Study: 16044027

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg twice daily for 6 months)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Ticlopidine (250 mg twice daily for 1 month)
Number of subjects: 397
Study: 12366505

Group type: EXPERIMENTAL
Intervention: Single thermistor catheter with cold injectate (0 degrees C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Single thermistor catheter with room temperature injectate (20 degrees C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dual thermistor catheter with cold injectate (0 degrees C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dual thermistor catheter with room temperature injectate (20 degrees C)
Number of subjects: 50
Study: 9952145

Group type: EXPERIMENTAL
Intervention: 0.7 MAC xenon with 0.6 MAC sevoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 MAC xenon with 0.3 MAC sevoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.7 MAC nitrous oxide with 0.6 MAC sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.3 MAC sevoflurane
Number of subjects: 40
Study: 7771102

Group type: EXPERIMENTAL
Intervention: Iontophoresis with local anaesthetics (0/6)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Iontophoresis with non-steroidal anti-inflammatory drugs (2/3)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Iontophoresis with vinca-alkaloids (1/2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Iontophoresis with corticosteroids (3/1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Iontophoresis with morphine (0/1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Iontophoresis with iodide (4/1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Iontophoresis with fluoride (0/1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo iontophoresis (lidocaine, procaine, flufenamic acid, diclofenac, Mobilat, vinca-alkaloids, dexamethasone-lidocaine, morphine, fluoride)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Topical administration (procaine, benzocaine-salicylamide, flufenamic acid)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo administration without current (procaine, flufenamic acid)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Other methods (lidocaine, iodide)
Number of subjects: 25
Study: 2178489

Group type: EXPERIMENTAL
Intervention: Midazolam and fentanyl (continuous infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Midazolam and fentanyl (intermittent bolus injections)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diazepam and fentanyl (continuous infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diazepam and fentanyl (intermittent bolus injections)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bolus technique
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous infusion
Number of subjects: 24
Study: 6777812

Group type: EXPERIMENTAL
Intervention: High Dose (250 mg per week)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low Dose (12.5 mg per week)
Number of subjects: 11
Study: 31526476

Group type: EXPERIMENTAL
Intervention: Higher intelligence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher educational attainment
Number of subjects: 0
Study: 28545657

Group type: EXPERIMENTAL
Intervention: TEGDMA/HEMA-free resin composite system with 3-step etch-and-rinse adhesive (cmf-els)
Number of subjects: 67

Group type: COMPARATOR
Intervention: 1-step HEMA-free self-etch adhesive (AdheSe One F)
Number of subjects: 67
Study: 26951309

Group type: EXPERIMENTAL
Intervention: Apitolisib 40 mg once per day
Number of subjects: 85

Group type: COMPARATOR
Intervention: Everolimus 10 mg once per day
Number of subjects: 85
Study: 25027140

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 120
Study: 22236497

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg/day for 6 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19151659

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 x 1 g daily for 6 months
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (fluocortolone and topical prednisolone acetate)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 17219171

Group type: EXPERIMENTAL
Intervention: RT-BW (non-instrumental resistance training using body weight as a load, 3 times per week for 12 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RT-BW
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 16368945

Group type: EXPERIMENTAL
Intervention: Single-view posterior-anterior chest radiograph
Number of subjects: 154942
Study: 12064338

Group type: EXPERIMENTAL
Intervention: Isomalt sweets
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sucrose sweets
Number of subjects: 67